|Quantity Discounts||1 - 2|
|3 - 4|
|5 - 6|
|7 - 9|
|10 - 9999|
Native Advertising: How Life Science Companies Can Keep the FTC and FDA Happy
With the increase of native advertising, both the FTC and the FDA are tightening up on enforcement.
According to the FTC, ads that are not conspicuous about their commercial nature may be viewed as unfair, which could invite a lawsuit on grounds of false advertising and unfair competition.
Register now to join AGG partners, Anuj Desai — partner of the Intellectual Property Practice Team — and Alan Minsk — partner and leader of the Food and Drug Practice Team — for a webinar CD and transcript that focuses on the potential risks that native advertising poses for life science companies, and learn how you can minimize those risks while continuing to engage in native advertising.
You will learn the following:
Order today and learn how to keep the FTC and FDA happy about your native advertising.
Meet Your Presenters
Anuj Desai is a partner in the Litigation Practice and Intellectual Property Team. Mr. Desai regularly appears in state and federal courts throughout the country, and he advises clients on dispute avoidance and dispute resolution in the areas of commercial and intellectual property litigation.
Alan G. Minsk is a partner and leader of the Food and Drug Practice Team. Mr. Minsk focuses his practice on advising pharmaceutical, biologic, medical device, cosmetic and food companies, on all legal and regulatory matters relating to the U.S. Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA).
Copyright ©2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing